These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

710 related items for PubMed ID: 14727946

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z.
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. What is the most effective strategy for managing diabetic dyslipidaemia?
    Reasner CA.
    Atheroscler Suppl; 2005 Sep; 6(3):21-7. PubMed ID: 16054442
    [Abstract] [Full Text] [Related]

  • 8. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M, Roberts A, Davies S, Rees A.
    Drugs; 2004 Sep; 64(11):1181-96. PubMed ID: 15161326
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. HDL-C: role as a risk modifier.
    Barter P.
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Role of fibric acid derivatives in the management of risk factors for coronary heart disease.
    Després JP, Lemieux I, Robins SJ.
    Drugs; 2004 Nov; 64(19):2177-98. PubMed ID: 15456334
    [Abstract] [Full Text] [Related]

  • 17. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
    da Silva PM.
    Am J Cardiovasc Drugs; 2011 Nov; 11(2):93-107. PubMed ID: 21446776
    [Abstract] [Full Text] [Related]

  • 18. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D, Keech A, Hunt D, Marschner I, Simes J, Glasziou P, White H, Barter P, Tonkin A, LIPID Study Investigators.
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [Abstract] [Full Text] [Related]

  • 19. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
    Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB, VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial.
    JAMA; 2001 Mar 28; 285(12):1585-91. PubMed ID: 11268266
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
    Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF.
    Arterioscler Thromb Vasc Biol; 2008 Jun 28; 28(6):1172-8. PubMed ID: 18356553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.